[1]包薇萍,刘超.巨分子促甲状腺激素的筛查策略[J].国际内分泌代谢杂志,2017,37(01):21-22，26.[doi:10.3760/cma.j.issn.1673-4157.2017.01.06]
　Bao Weiping,Liu Chao..Screening strategy for macro-thyroid-stimulating hormone[J].International Journal of Endocrinology and Metabolism,2017,37(01):21-22，26.[doi:10.3760/cma.j.issn.1673-4157.2017.01.06]
点击复制

巨分子促甲状腺激素的筛查策略()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年01期
页码:
21-22，26
栏目:
综述
出版日期:
2017-01-20

文章信息/Info

Title:
Screening strategy for macro-thyroid-stimulating hormone
作者:
包薇萍; 刘超
210028 南京中医药大学附属中西医结合医院内分泌科,江苏省中医药研究院
Author(s):
Bao Weiping;  Liu Chao.
Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China
关键词:
巨分子促甲状腺激素;  筛查;  凝胶过滤层析法
Keywords:
Macro-thyroid-stimulating hormone;  Screening strategy;  Gel filtration chromatography
DOI:
10.3760/cma.j.issn.1673-4157.2017.01.06
摘要:
巨分子促甲状腺激素(TSH)是TSH与抗TSH免疫球蛋白形成的大分子复合物,是一种少见的实验室干扰物,可引起TSH假性升高。为了避免误诊亚临床甲状腺功能减退症,临床遇到单纯TSH升高需考虑巨分子TSH的存在。制定巨分子TSH筛查策略是至关重要的。凝胶过滤层析法有助于发现这种罕见的物质。
Abstract:
Macro-thyroid-stimulating hormone(TSH)is a macromolecule that is formed between autoimmune anti-TSH Ig and TSH molecule. It is a rare laboratory interference that can interfere with laboratory measurement of TSH, leading to spuriously high results. To avoid misdiagnosis of subclinical hypothyroidism, the possibility of macro-TSH, in cases with TSH values higher than expected should be considered. Screening strategy for macro-TSH is crucially important. Gel filtration chromatography can help to diagnose this rare entity.

参考文献/References:

[1] 李继尧.促甲状腺激素的神经内分泌调节[J]. 生物学通报,1998,33(10):26-28.
[2] Sakai H, Fukuda G, Suzuki N,et al. Falsely elevated thyroid-stimulating hormone(TSH)level due to macro-TSH[J].Endocr J,2009,56(3):435-440.
[3] Spira O, Gafni M, Ben-David C,et al. TSH binding proteins in rat and human serum[J]. Acta Endocrinol(Copenh), 1987,115(4):497-506.
[4] Estrada JM, Soldin D, Buckey TM,et al. Thyrotropin isoforms: implications for thyrotropin analysis and clinical practice[J].Thyroid, 2014,24(3):411-423. DOI: 10.1089/thy.2013.0119.
[5] Loh TP, Kao SL, Halsall DJ,et al. Macro-thyrotropin: a case report and review of literature[J].J Clin Endocrinol Metab,2012,97(6):1823-1828. DOI: 10.1210/jc.2011-3490.

相似文献/References:

[1]中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南(2021年版)[J].国际内分泌代谢杂志,2021,41(04):388.[doi:10.3760/cma.j.cn121383-20210825-08064]
　Microvascular Complications Group of Chinese Diabetes Society.Clinical guideline for the prevention and treatment of diabetic kidney disease in China(2021 edition)[J].International Journal of Endocrinology and Metabolism,2021,41(01):388.[doi:10.3760/cma.j.cn121383-20210825-08064]
[2]吴静,冉兴无.糖尿病下肢动脉病变的早期筛查与规范化管理[J].国际内分泌代谢杂志,2021,41(06):587.[doi:10.3760/cma.j.cn121383-20210922-09064]
　Wu Jing,Ran Xingwu..Early screening and standardized management of artery disease in diabetic lower extremity[J].International Journal of Endocrinology and Metabolism,2021,41(01):587.[doi:10.3760/cma.j.cn121383-20210922-09064]
[3]许媛 许岚 张丽华 李启富 杨淑敏.中国原发性醛固酮增多症诊断现状调查研究[J].国际内分泌代谢杂志,2022,42(04):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
　Xu Yuan,Xu Lan,Zhang Lihua,et al.Investigation on current status of diagnosis of primary aldosteronism in China[J].International Journal of Endocrinology and Metabolism,2022,42(01):288.[doi:10.3760/cma.j.cn121383-20201221-12058]

备注/Memo

备注/Memo:
通信作者:刘超,Email:liuchao@nfmcn.com
更新日期/Last Update: 2017-01-20